<DOC>
	<DOCNO>NCT02664363</DOCNO>
	<brief_summary>Newly diagnose glioblastoma subject eligible enrol follow surgery remove brain tumor . They undergo leukapheresis harvest cell generation study drug , Epidermal Growth Factor variant III Chimeric Antigen Receptor ( EGFRvIII CAR ) T cell prior begin standard care ( SOC ) radiation therapy ( RT ) temozolomide ( TMZ ) . Once SOC RT TMZ complete , subject return post-RT brain imaging assessment , stable start post-RT TMZ cycle . During 3rd cycle post-RT TMZ , EGFRvIII CAR T cell infuse dose escalation cohort . Following one month delay cycle , subject resume post-RT cycle TMZ monitor blood work brain image per SOC . Once maximally tolerate dose ( MTD ) reach dose escalation cohort , expand cohort 12 subject enrol obtain precise estimate probability unacceptable toxicity track EGFRvIII CAR T cell use 111 Indium ( 111In ) labeling . Computed Tomography ( CT ) do day 1 , 5 , 10 post-infusion determine intracerebral ( IC ) localization .</brief_summary>
	<brief_title>EGFRvIII CAR T Cells Newly-Diagnosed GBM</brief_title>
	<detailed_description>Following consent , subject enrol onto dose-escalation cohort . Patients undergo leukapheresis harvest Peripheral Blood Mononuclear Cells ( PBMCs ) generation EGFRvIII CAR T cell prior begin RT concurrent TMZ . T cell isolate patient 's PBMCs transduce express S. Briefly , PBMC stimulate Muromonab-cluster differentiation 3 ( CD3 ) ( OKT3 ) , anti-CD3 monoclonal antibody ( mAb ) transduce RetroNectin® coat plate . Transduced cell expand interleukin-2 ( IL-2 ) 14 day . Patients complete 6 week standard care RT concurrent TMZ target dose 75 mg/m^2/d . Patients experience progressive disease radiation , unable tolerate TMZ , require TMZ dose modification withdrawn study replace . The remain patient receive initial cycle TMZ 50-100 mg/m^2/day 21 day , follow 2 cycle 100 mg/m^2/day 21 day every 28 day , standard dose-intensified ( DI ) TMZ regimen . If patient unable tolerate DI TMZ CAR-specific T cell meet release criterion , patient withdrawn CAR treatment replace . On day 22 ( +3 day window ) third post-radiation cycle DI TMZ , total dose EGFRvIII CAR T cell deliver intravenously . If sufficient CAR-specific T cell generate meet target assign dose within dose-escalation portion study , patient treat low pre-defined dose level use available CAR-specific T cell replace assign high dose . The administered dose high define dose level sufficient CAR-specific T cell available . Within expand cohort , sufficient CAR-specific T cell ca n't generate meet MTD dose , available T cell administer . Following infusion EGFRvIII CARs , blood sample immune monitor drawn 1 , 5 , 10 day infusion , 1 , 3 , 6 month , yearly progression ( death lose contact ) . The return visit immune monitoring 3 , 6 , yearly coincide standard care clinic visit . Blood also take Replication Competent Retrovirus ( RCR ) Polymerase Chain Reaction ( PCR ) per Food Drug Administration ( FDA ) 3 , 6 12 month standard care clinic visit . Lastly , blood evaluation cytokine release syndrome ( CRS ) drawn prior cell infusion , 1 4 hour infusion , day 1 , 2 , 5 , 10 , one month . Measurements CRS include IL-2 , IL-6 , Tumor Necrosis Factor alpha ( TNFα ) , interferon ( IFN ) gamma , Granulocyte-macrophage colony-stimulating factor ( GM-CSF ) , C-reactive protein ( CRP ) . Patients return clinic one month follow EGFRvIII CAR T cell infusion evaluate cycle standard care 5-day TMZ 150-200 mg/m^2/day first 5-day cycle , follow 200 mg/m^2/day 5-days every 28 day per treat oncologist . This result 28-day delay TMZ cycle 3 4 order decrease chance study drug washout TMZ . Tumor progression document histologically , unless clinical contraindication , exclude inflammatory response present radiographic clinical change , could indicate potentially toxic therapeutic response tumor progression . If tissue obtain Tissue Bank Consent Institutional Review Board ( IRB ) # 2635 , use confirm tumor progression histologically , assess immunologic cell infiltration EGFRvIII antigen escape tumor site . Patients eligible additional adjuvant therapy time tumor progression . A classical `` 3+3 '' study design use estimate MTD CAR-specific T cell treatment among patient newly-diagnosed GBM . Four dose level consider : # 1 : 4.5 x 10^6/kg , # 2 : 1.5 x 10^7/kg , # 3 : 4.5 x 10^7/kg , # 4 : 1.5 x 10^8/kg.Starting low dose level , cohorts 3-6 subject accrue dose level . If patient lose follow-up first 4 week CAR treatment without experience dose-limiting toxicity ( DLT ) , patient evaluable determination DLT replace . The MTD high dose level ≤1 6 patient experience DLT 4 week observation period CAR treatment . An expand cohort total 12 patient enrol MTD EGFRvIII CAR T cell order obtain precise estimate probability unacceptable toxicity . This cohort also cell radiolabeled 111In track distribution . Briefly , CARs count re-suspended phosphate buffer saline ( PBS ) . 4-6x10^8 cell label 500 microCi 111In . The cell wash mixed cold CARs achieve desire cell dose . The labeled CARs infuse patient intravenous catheter within Ambulatory Bone Marrow Transplant ( BMT ) Unit . Distribution 111In-labeled EGFRvIII CARs evaluate 1 , 5 10 day post-infusion use scintigraphy .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>1 . Age 1880 year age 2 . Histopathologically proven newlydiagnosed , supratentorial malignant primary brain tumor ( World Health Organization ( WHO ) Grade IV GBM ) undergone surgical biopsy excision residual disease ( &gt; 2cm ) . 3 . Karnofsky Performance Status ( KPS ) score ≥ 70 . 4 . The presence target antigen , EGFRvIII , must identify tumor tissue immunohistochemistry ( IHC ) Polymerase Chain Reaction ( PCR ) . 5 . Stable decrease steroid dose within 5 day prior enrollment . 6 . Hematology : White Blood Count ( WBC ) ≥ 3000/mm^3 Absolute Neutrophil Count ( ANC ) ≥ 1000/mm^3 without support filgrastim Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 8.0 g/dl 7 . Chemistry : Alanine Amino Transferase ( ALT ) /Aspartate Amino Transferase ( AST ) ≤ 2.5 time upper limit normal Creatinine ≤ 1.6 mg/dl Total bilirubin ≤ 1.5 mg/dl . 1 . Patients pregnant , breastfeeding , unwilling practice effective method birth control . 2 . Patients know potentially anaphylactic allergic reaction GadoliniumDiethylene Triamine Pentaacetic Acid ( gdDTPA ) . 3 . Patients undergo Magnetic Resonance Imaging ( MRI ) Single Photon EmissionComputed Tomography ( SPECT ) due obesity certain metal body ( specifically pacemaker , infusion pump , metal aneurysm clip , metal prosthesis , joint , rod , plate ) . 4 . Patients evidence tumor brainstem , cerebellum , spinal cord , radiological evidence multifocal disease , leptomeningeal disease . 5 . Active infection require treatment unexplained febrile ( &gt; 101.5o F ) illness . 6 . Known autoimmune disease , immunosuppressive disease human immunodeficiency virus ( HIV ) infection ( i.e. , know HIV Hepatitis C ) . 7 . Patients unstable severe intercurrent medical condition severe heart lung disease . 8 . Patients previous history radiosurgery , brachytherapy , gliadel implantation , radiolabeled monoclonal antibody . 9 . Prior antitumor therapy glioma ( steroid ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>